Everolimus (RAD001)

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Neuroendocrine Tumors

Conditions

Neuroendocrine Tumors

Trial Timeline

Apr 27, 2011 → Aug 9, 2016

NCT ID

NCT01595009

About Everolimus (RAD001)

Everolimus (RAD001) is a approved stage product being developed by Novartis for Neuroendocrine Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT01595009. Target conditions include Neuroendocrine Tumors.

What happened to similar drugs?

5 of 15 similar drugs in Neuroendocrine Tumors were approved

Approved (5) Terminated (2) Active (9)

🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

🔄68Ga-DOTATOCJiangsu Hengrui MedicinePhase 3

🔄Everolimus + Everolimus PlaceboNovartisPhase 3

✅Pasireotide + DiazoxideNovartisApproved

🔄[68Ga]Ga-DOTA-TATE + 68Ge/68Ga GeneratorNovartisPhase 3

✅everolimusNovartisApproved

🔄Drug: Everolimus + STZ-5FUNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01514448	Approved	Completed	May 21, 2012	Apr 1, 2016	Metastatic Renal Cell Carcinoma (mRCC)
NCT01365468	Phase 2	Terminated	Apr 1, 2012	Apr 1, 2015	Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
NCT01595009	Approved	Completed	Apr 27, 2011	Aug 9, 2016	Neuroendocrine Tumors
NCT01152801	Phase 1	Completed	May 1, 2010	Dec 1, 2013	Metastatic Renal Cell Carcinoma
NCT01022996	Phase 2	Completed	Dec 1, 2009	Nov 1, 2014	Hodgkin Lymphoma
NCT00792766	Phase 1/2	Completed	Dec 1, 2008	Sep 1, 2013	Tuberous Sclerosis
NCT00426530	Phase 1	Completed	Feb 1, 2007	Jun 1, 2010	Breast Neoplasms
NCT00419159	Phase 2	Completed	Dec 1, 2006	Mar 1, 2009	Colorectal Cancer
NCT00154297	Approved	Completed	Jun 1, 2005	—	Renal Transplantation
NCT00170794	Phase 3	Completed	Sep 1, 2004	—	Cardiac Transplantation
NCT00531440	Phase 3	Completed	Nov 1, 2001	—	Renal Transplantation
NCT00531063	Phase 3	Completed	Nov 1, 2001	—	Renal Transplantation

Competing Products

20 competing products in Neuroendocrine Tumors

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27
Lenvatinib	Eisai	Phase 2	35
Abemaciclib	Eli Lilly	Phase 2	39
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.	Jiangsu Hengrui Medicine	Phase 3	47
Famitinib	Jiangsu Hengrui Medicine	Phase 2	27
68Ga-DOTATOC	Jiangsu Hengrui Medicine	Phase 3	47
Olaparib	AstraZeneca	Phase 2	27
Avelumab	Merck	Phase 1/2	32
Pembrolizumab	Merck	Phase 2	27
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	35
Pembrolizumab Injection	Merck	Phase 2	27
Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab	Merck	Phase 1	33
Avelumab	Merck	Phase 2	35
Pembrolizumab + Lenvatinib	Merck	Phase 2	35
Avelumab	Merck	Phase 2	35
Pembrolizumab + Irinotecan + Paclitaxel	Merck	Phase 2	35
MK-0646	Merck	Phase 2	35